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Key Clinical Message
We report a patient with developmental delay due to germline AUTS2 muta-
tion who developed a low-grade astrocytoma. While the contribution of this
mutation to the pathogenesis of the tumor is not known at this time, a role of
AUTS2 in deregulation of PRC1 can be a part in tumorigenesis of a brain
tumor.
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Background
In this case report, we describe a first patient with a low-
grade astrocytoma and a deletion in the AUTS2 gene.
Mutations in (parts of) the autism susceptibility candidate
2 (AUTS2) are described in case reports and further
explored in animal models. The hypothesis is that the
AUTS2 protein has an important role in axon guidance,
dendrite elaboration, synaptogenesis or related aspects of
neuronal development, but the exact function is not
known. The phenotype has a wide range of features with
intellectual disability, autism, and dysmorphic features. A
role in tumorigenesis of brain tumors is not yet proved.
Low-grade gliomas are the most common central ner-
vous system tumors in childhood. Benign cerebellar astro-
cytomas are most prevalent, accounting for 15–25% of all
central nervous system tumors [1, 2]. Diffuse astrocy-
tomas account for approximately 5% of all tumors in
children aged 0–14 years [3]. Malignant transformation in
most low-grade tumors is rare [2]. First treatment of
choice is complete resection of the tumor. After surgery,
the long-term results are good.
With time more is known about tumorigenesis. Mito-
gen-activated protein kinase (MAPK) pathway activation
drives the formation of most low-grade gliomas (LGG).
The most common mechanism of a MAPK pathway acti-
vation in LGG’s is a tandem duplication on chromosome
7q34. In addition, deletions in 7q34 are described [4].
Astrocytomas are occasionally described in Noonan,
Turner, Lynch syndrome, and neurofibromatosis.
We present a patient with a low-grade astrocytoma and
a deletion of chromosome 7q11.22.
Clinical Case Report
Our patient is the fifth child of nonconsanguineous
Dutch parents. His eldest sister has ADHD and a mild
intellectual disability (ID). His other sister and two broth-
ers are healthy. The son of his father’s sister has a colo-
boma of both eyes and a mild mental retardation.
Our patient was born term after normal pregnancy and
no complications during and after delivery. He was diag-
nosed with a coloboma of the left eye in the neonatal per-
iod and at the age of 5 years, he was diagnosed with a
mild intellectual disability (IQ 72) and he is following
special education.
At the age of 12 years, he was evaluated for a small sta-
ture which was related to a late puberty. His puberty
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started at the age of fifteen and he reached a normal
height.
In 2013, he had his first generalized tonic-clonic epilep-
tic seizure treated in the emergency department.
In the past 6 months, he had episodes of bilateral tin-
nitus with dizziness and difficulty speaking. During these
episodes, duration of 30 sec and approximately three
times a week, he turns his head to the left side and par-
ents noticed an impairment of consciousness. After the
episode, he complains of nausea and headache. These epi-
sodes were diagnosed as complex partial seizures.
On physical examination, we found mild dysmor-
phisms: hypotelorism, a broad forehead, a broad nose
bridge, a full nose tip, and full lips. He has long feet and
arms with a cubitus valgus.
We performed an EEG and a MRI of the brain. The
EEG showed mild diffuse slowing of the right hemisphere,
but no epileptic activity. The MRI of the brain showed a
hyperintense lesion on T2 and flair images in the right
temporal lobe, with enhancement after admission of
gadolinium. The radiological differential diagnosis
included ganglioglioma, DNET, or low-grade astrocytoma
(Fig. 1).
Consequently, he was operated in an academic hospital
and the tumor was completely removed. Pathology shows
a diffuse infiltrating low-grade astrocytoma (Fig. 2).
No adjuvant therapy was given.
A MRI of the brain 6 months after surgery did not
show residual tumor or recurrence of the tumor. After
resection of the astrocytoma, the patient no longer suf-
fered from seizures and a year after surgery, the
antiepileptic drugs were successfully stopped. Follow-up
will be every 9 months until at least 5 years after the sur-
gery.
Results
The combination of a coloboma, a mild intellectual dis-
ability, a late puberty, mild dysmorphisms, and an epilep-
tic seizure could well have a genetic cause, such as
CHARGE syndrome. Tumors including a low-grade astro-
cytoma can be part of various syndromes.
We performed a SNP-array on total genomic DNA
extracted from leucocytes. The Illumina Human Cyto 12-
SNP genotyping array was used in combination with the
Illumina iScan Control and the Nexus Copy Number 7.0
Figure 1. (A) Flair image with hyperintense lesion in the right temporal lobe (indicated by an arrow). (B) Flair image with hyperintense lesion in
the right temporal lobe (indicated by a red line).
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software BioDiscovery El Segundo California, USA
according to standard protocols of the manufacturer.
A deletion of 457 kb in band 7q11.22 (chr7:
68,910,981–69,367,635) was found. This loss includes 61
probes and a part of AUTS2 including some exons (exon
2, 3 and 4).
In June 2015, we performed a whole-exome sequencing
also on total genomic DNA extracted from leucocytes for
genes involved with ID, epilepsy, autism, and neuronal
migration disorders. The WES did not show any causative
mutations.
Pathology of the tumor shows a low-grade diffuse
astrocytoma, IDH-wildtype, WHO grade 1 (correspond-
ing to the 2016 WHO Classification system for CNS
tumors).
Further genetic testing shows a point mutation in the
BRAF v600e gene. This mutation is seen in <10% of all
pilocytic astrocytomas.
Discussion
Autism susceptibility candidate 2 (AUTS2) is located on
chromosome 7q11.22 and spans 1.2 MB of the genomic
DNA. AUTS2 consist of 19 exons where the first half of
the gene (exon 1–6) has relatively large introns and the
second half (exons 7–19, C-terminus) has smaller clus-
tered introns. The exact function of AUTS2 is unknown,
but deletions in the AUTS2 region gives a wide range of
syndromic phenotypes, including intellectual disability,
autism, microcephaly, short stature, hypotonia, cerebral
palsy, and dysmorphic features. The phenotype can be
subtle, and the severity of the syndrome is highly variable.
Furthermore, the location and the type of deletion are
important for the resulting phenotype, with a more severe
phenotype with deletions in the C-terminus [5]. A recent
study of Beunders et al. described 13 patients (including
six adults) with AUTS2 syndrome with unique pathogenic
deletions scattered around the AUTS2 locus and confirm
a phenotype–genotype correlation [6].
The AUTS2 protein also plays an important role in neu-
rodevelopment. Earlier studies with knockdown AUTS2
zebrafish shows a reduction in motor and sensory neurons
in the spinal cord and developing neurons in regions that
include the midbrain and cerebellum, which resulted in
reduced movement and decreased response to touch [5, 7].
Mouse studies show that there is expression of AUTS2 in
developing neurons in the frontal cortex and cerebellum.
This suggests that AUTS2 could be important for migra-
tion, axon guidance, dendrite elaboration, synaptogenesis,
or related aspects of neuronal development [8].
The study of Hori et al. suggests that AUTS2 may also
have a cytoplasmic role in cytoskeletal regulation, in addi-
tion to its nuclear function, and indicate that cytoplasmic
AUTS2 is involved in cortical neuronal migration [9].
They did not observe abnormal apoptosis or proliferation
of cells in any of their AUTS2 mutant mouse brains.
Gao et al. show a role for AUTS2 in modulating the
role of polycomb repressor complex 1 (PRC1) from a
repressive function to transcription stimulation in the
AUTS2-PRC1 complex. In this way, AUTS2 plays a role
in regulation of neuronal gene expression through pro-
moter association. Their hypothesis is that changes in
AUTS2 result in reduced neuronal gene expression trough
the AUTS2-PRC1 complex and can give different develop-
mental defects [10]. Polycomb group proteins play an
important role in neurodevelopment, but deregulation
can lead to oncogenesis. Deregulation of PRC1 plays a
role in formation and progression of glioblastomas [11].
BMI1 or polycomb group ring finger protein 4, which is
part of PRC1, has a role in the suppression of p16INK4a
[12]. Lack of expression of p16INK4a next to a BRAF
v600e mutation, gives less senescence and more tumor
growth, where a BRAF v600e mutation alone is sufficient
to promote only some aspects of oncogenic transforma-
tion [13]. Probably changes in the AUTS2 gene can result
in deregulation of PRC1 through changes in the AUTS2-
PRC1 complex.
The possibility that this patient has two rare diseases
which are not linked to each other can not be fully
excluded, but may be less likely.
Conclusions
This is the first case description of a patient with a muta-
tion in the AUTS2 gene and a brain tumor, in this case a
low-grade astrocytoma. Both the exact function of the
Figure 2. Photomicrograph of the tumour histology.
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AUTS2 protein and the neurodevelopment of low-grade
gliomas are not yet known. There is a possible role for
the AUTS2 gene in the development of low-grade gliomas
via migration, axon guidance, dendrite elaboration,
synaptogenesis, or related aspects of neuronal develop-
ment. There may also be a role in tumorigenesis for the
AUTS2 protein by deregulation of PRC1.
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